In recent months, the issue of whether certain patents are appropriately listed in the Food and Drug Administration (FDA) Orange Book, associated with the Hatch-Waxman Act, has garnered the attention of the Federal Trade...more
6/18/2024
/ Abbreviated New Drug Application (ANDA) ,
Federal Trade Commission (FTC) ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Medical Devices ,
Orange Book ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs
Trade secret litigation is on the rise, and new case law related to enforceability has broad implications for how companies protect information that they consider to be trade secrets.
The Lex Machina 2020 Trade Secret...more
2/25/2021
/ Confidential Information ,
Corporate Counsel ,
Defend Trade Secrets Act (DTSA) ,
Employer Liability Issues ,
Exit Interviews ,
Former Employee ,
Intellectual Property Protection ,
Life Sciences ,
Patent Litigation ,
Technology ,
Trade Secrets
Written Description of Therapeutic Efficacy -
In two 2019 rulings, the Federal Circuit invoked the “written description requirement” of 35 U.S.C. § 112 to require evidentiary support for therapeutic efficacy. Now that the...more
2/24/2021
/ Appeals ,
Copyright ,
Defend Trade Secrets Act (DTSA) ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Misappropriation ,
Patent-Eligible Subject Matter ,
Pharmaceutical Patents ,
Section 101 ,
Social Media ,
Trade Secrets ,
USPTO ,
Written Descriptions